MindWalk Holdings Corp. to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2026 on December 15, 2025

MindWalk Holdings Corp. (NASDAQ:HYFT) (“MindWalk” or the “Company”), a Bio-Native AI therapeutic research and technology company, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for second quarter fiscal year 2026, on Monday, December 15, 2025, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call. MindWalk management will host the conference call followed by a question-and-answer period.

Conference Call and Webcast Details

The Company will host a live conference call and webcast to discuss these results and provide a corporate update on Monday, December 15, 2025, at 10:30AM ET.

The conference call will be webcast live and available for replay via a link provided in the Events section of the Company’s IR pages at:

https://ir.mindwalkai.com/events-and-presentations/default.aspx

Participant Dial-in:
USA / International Toll +1 (646) 307-1963
USA - Toll-Free (800) 715-9871
Canada - Toronto (647) 932-3411
Canada - Toll-Free (800) 715-9871
Conference ID: 3224490

* Webcast Details *
Event Title: MindWalk Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2026

Attendee URL:
https://events.q4inc.com/attendee/410261259

Anyone listening to the call is encouraged to read the company's periodic reports available on the company’s profile at www.sedarplus.com and www.sec.gov , including the discussion of risk factors and historical results of operations and financial condition in those reports.

About MindWalk
MindWalk is a Bio-Native AI company transforming drug discovery and development. Powered by patented HYFT ^® technology and the LensAI™ platform, MindWalk unifies sequence, structure, function, and literature into a single computational language and closes the loop with an integrated, full-stack wet lab. The platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration, and population-scale biologics analytics that help turn insights into validated candidates at speed.

Source: MindWalk Holdings Corp.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251208893679/en/